YMAB NASDAQ

Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma in children when the disease has returned or proven resistant to prior treatments. Beyond its approved indication, DANYELZA is undergoing Phase II trials for new applications, including initial and third-line neuroblastoma, as well as relapsed osteosarcoma. Furthermore, Y-mAbs is progressing with a GD2-GD3 vaccine, currently in Phase II for aggressive Stage 4 neuroblastoma. Another key asset, Omburtamab, a murine monoclonal antibody, is being evaluated in clinical studies for a range of challenging conditions: central nervous system and leptomeningeal spread of neuroblastoma, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other cancers expressing the B7-H3 protein. The company's pipeline also features Nivatrotamab, which is being investigated for small cell lung cancer and is in Phase I/II trials for persistent GD2-positive solid tumors in both adult and pediatric populations. Completing its early-stage portfolio is Lu-omburtamab-DTPA, a Phase I candidate aimed at treating medulloblastoma and B7-H3 positive leptomeningeal metastases originating from solid tumors. Y-mAbs maintains a licensing arrangement with both the Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, enabling it to advance and market certain agreed-upon therapies. Established in 2015, Y-mAbs Therapeutics, Inc. operates from its headquarters in New York City.